Demystifying triglycerides: a practical approach for the clinician.
Because the landmark trials of lipid-lowering statin drugs excluded patients with very high triglyceride levels, the optimal management of hypertriglyceridemia for atherosclerosis prevention is unknown. The third report of the National Cholesterol Education Program's Adult Treatment Panel (ATP-III) provides a much-needed strategy for managing patients with high triglycerides, based on the best available evidence.
Dunbar
Richard L
RL
Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA. richard.dunbar@uphs.upenn.edu
Rader
Daniel J
DJ
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control*; D002995:Clofibric Acid / Q000627:therapeutic use; D005395:Fish Oils / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000503:physiopathology; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D008019:Life Style; D008075:Lipoproteins, HDL / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000187:drug effects; D009525:Niacin / Q000627:therapeutic use; D014280:Triglycerides / Q000009:adverse effects / Q000378:metabolism*
D005395:Fish Oils; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D009525:Niacin; D002995:Clofibric Acid